{"id":1695,"date":"2014-03-13T10:33:37","date_gmt":"2014-03-13T10:33:37","guid":{"rendered":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=1695"},"modified":"2014-03-14T07:04:15","modified_gmt":"2014-03-14T07:04:15","slug":"risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\/","title":{"rendered":"Risikoprofil von Dronedaron inakzeptabel. PALLAS-Studie gestoppt"},"content":{"rendered":"<p>AMB 2011,\u00a045, 59a &nbsp; Risikoprofil von Dronedaron inakzeptabel. PALLAS-Studie gestoppt &nbsp; \u00dcber die Ergebnisse der Zulassungsstudien zu Dronedaron (Multaq\u00ae) haben wir ausf\u00fchrlich berichtet und die vielen offenen Fragen zu Wirksamkeit und Vertr\u00e4glichkeit bei dieser Indikation \u2013 vor allem im direkten Vergleich mit Amiodaron \u2013 aufgelistet (1). Dronedaron ist zugelassen f\u00fcr erwachsene, klinisch stabile Patienten mit [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AMB 2011,\u00a045, 59a &nbsp; Risikoprofil von Dronedaron inakzeptabel. PALLAS-Studie gestoppt &nbsp; \u00dcber die Ergebnisse der Zulassungsstudien zu Dronedaron (Multaq\u00ae) haben wir ausf\u00fchrlich berichtet und die vielen offenen Fragen zu Wirksamkeit und Vertr\u00e4glichkeit bei dieser Indikation \u2013 vor allem im direkten Vergleich mit Amiodaron \u2013 aufgelistet (1). Dronedaron ist zugelassen f\u00fcr erwachsene, klinisch stabile Patienten mit [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[199,850],"tags":[200,605,606,121,853,122,204],"class_list":["post-1695","post","type-post","status-publish","format-standard","hentry","category-jahr-2011-band-45","category-monat-8","tag-absolute-arrhythmie","tag-antiarrhythmika","tag-dronedaron","tag-herzrhythmusstoerungen","tag-pallas-studie","tag-rhythmusstoerungen","tag-vorhofflimmern"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Risikoprofil von Dronedaron inakzeptabel. PALLAS-Studie gestoppt<\/title>\n<meta name=\"description\" content=\"\u00dcber die Ergebnisse der Zulassungsstudien zu Dronedaron (Multaq\u00ae) haben wir ...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Risikoprofil von Dronedaron inakzeptabel. PALLAS-Studie gestoppt\" \/>\n<meta property=\"og:description\" content=\"\u00dcber die Ergebnisse der Zulassungsstudien zu Dronedaron (Multaq\u00ae) haben wir ...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2014-03-13T10:33:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2014-03-14T07:04:15+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg\" \/>\n<meta name=\"author\" content=\"henk-amb\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"henk-amb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\\\/\"},\"author\":{\"name\":\"henk-amb\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"headline\":\"Risikoprofil von Dronedaron inakzeptabel. PALLAS-Studie gestoppt\",\"datePublished\":\"2014-03-13T10:33:37+00:00\",\"dateModified\":\"2014-03-14T07:04:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\\\/\"},\"wordCount\":473,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"keywords\":[\"Absolute Arrhythmie\",\"Antiarrhythmika\",\"Dronedaron\",\"Herzrhythmusst\u00f6rungen\",\"PALLAS-Studie\",\"Rhythmusst\u00f6rungen\",\"Vorhofflimmern\"],\"articleSection\":[\"Jahr 2011 Band 45\",\"Monat 8\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\\\/\",\"name\":\"Risikoprofil von Dronedaron inakzeptabel. PALLAS-Studie gestoppt\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"datePublished\":\"2014-03-13T10:33:37+00:00\",\"dateModified\":\"2014-03-14T07:04:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"description\":\"\u00dcber die Ergebnisse der Zulassungsstudien zu Dronedaron (Multaq\u00ae) haben wir ...\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Risikoprofil von Dronedaron inakzeptabel. PALLAS-Studie gestoppt\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\",\"name\":\"henk-amb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"caption\":\"henk-amb\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Risikoprofil von Dronedaron inakzeptabel. PALLAS-Studie gestoppt","description":"\u00dcber die Ergebnisse der Zulassungsstudien zu Dronedaron (Multaq\u00ae) haben wir ...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\/","og_locale":"de_DE","og_type":"article","og_title":"Risikoprofil von Dronedaron inakzeptabel. PALLAS-Studie gestoppt","og_description":"\u00dcber die Ergebnisse der Zulassungsstudien zu Dronedaron (Multaq\u00ae) haben wir ...","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2014-03-13T10:33:37+00:00","article_modified_time":"2014-03-14T07:04:15+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","type":"","width":"","height":""}],"author":"henk-amb","twitter_misc":{"Verfasst von":"henk-amb","Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\/"},"author":{"name":"henk-amb","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"headline":"Risikoprofil von Dronedaron inakzeptabel. PALLAS-Studie gestoppt","datePublished":"2014-03-13T10:33:37+00:00","dateModified":"2014-03-14T07:04:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\/"},"wordCount":473,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","keywords":["Absolute Arrhythmie","Antiarrhythmika","Dronedaron","Herzrhythmusst\u00f6rungen","PALLAS-Studie","Rhythmusst\u00f6rungen","Vorhofflimmern"],"articleSection":["Jahr 2011 Band 45","Monat 8"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\/","name":"Risikoprofil von Dronedaron inakzeptabel. PALLAS-Studie gestoppt","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","datePublished":"2014-03-13T10:33:37+00:00","dateModified":"2014-03-14T07:04:15+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"description":"\u00dcber die Ergebnisse der Zulassungsstudien zu Dronedaron (Multaq\u00ae) haben wir ...","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/risikoprofil-von-dronedaron-inakzeptabel-pallas-studie-gestoppt\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Risikoprofil von Dronedaron inakzeptabel. PALLAS-Studie gestoppt"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937","name":"henk-amb","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","caption":"henk-amb"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/1695","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=1695"}],"version-history":[{"count":2,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/1695\/revisions"}],"predecessor-version":[{"id":1713,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/1695\/revisions\/1713"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=1695"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=1695"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=1695"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}